Emily N. Prendergast

Emily N. Prendergast, MD, FACOG

Languages spoken: English

Academic Information

Departments Adjunct - Obstetrics & Gynecology

Divisions: Gynecological Oncology

Academic Office Information

Emily.Prendergast@hsc.utah.edu

Board Certification

  • American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
  • American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

Education History

Fellowship University of California, Los Angeles, Cedars-Sinai
 Fellow
Northwestern University Feinberg School of Medicine
 Resident
Professional Medical University of Arizona College of Medicine – Tucson
 MD
University of Arizona
 BS

Selected Publications

Journal Article

  1. Mirza MR, Gonzlez-Martn A, Graybill WS, OMalley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ (2023). Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Cancer, 129(12), 1846-1855. (Read full article)
  2. Blank SV, Huh WK, Bell M, Dilley S, Hardesty M, Hoskins ER, Lachance J, Musa F, Prendergast E, Rimel BJ, Shahin M, Valea F (2023). Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report. Gynecol Oncol, 171, 76-82. (Read full article)
  3. Monk BJ, Parkinson C, Lim MC, OMalley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS (2022). A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol, 40(34), 3952-3964. (Read full article)
  4. Esselen K, Sinno AK, Varughese J, Wethington SL, Prendergast E, Chu CS (2020). Social needs in gynecologic oncology: A Society of Gynecologic Oncology (SGO) clinical practice statement. Gynecol Oncol, 158(3), 521-525. (Read full article)
  5. Prendergast EN, Holman LL, Liu AY, Lai TS, Campos MP, Fahey JN, Wang X, Abdelaal N, Rao JY, Elvin JA, Moore KM, Konecny GE, Cohen JG (2019). Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol, 154(3), 461-466. (Read full article)
  6. Liang MI, Prendergast EN, Staples JN, Holschneider CH, Cohen JG, Cass I (2019). Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. J Surg Oncol, 120(4), 779-785. (Read full article)
  7. Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES (2019). Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. Int J Gynecol Cancer, 29(7), 1156-1163. (Read full article)
  8. Prendergast EN, de Souza Fonseca MA, Dezem FS, Lester J, Karlan BY, Noushmehr H, Lin X, Lawrenson K (2018). Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens. PLoS One, 13(5), e0196913. (Read full article)
  9. Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, Karlan BY, Mackman N, Walsh CS (2017). Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol, 146(1), 146-152. (Read full article)
  10. Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM Jr, Gunderson CC, Moore KN, Erickson BK, Leath CA 3rd, Diaz Moore ES, Cohen JG, Walsh CS (2016). Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol, 144(2), 274-278. (Read full article)
  11. Prendergast E, Silver H, Johnson LL, Simon M, Feinglass J, Kielb S, Hairston J, Lewicky-Gaupp C (2015). Anatomic Outcomes of Robotic Assisted Supracervical Hysterectomy and Concurrent Sacrocolpopexy at a Tertiary Care Institution at Initial Adaptation of the Procedure. Female Pelvic Med Reconstr Surg, 22(1), 29-32. (Read full article)
  12. Mayta H, Gilman RH, Prendergast E, Castillo JP, Tinoco YO, Garcia HH, Gonzalez AE, Sterling CR, Cysticercosis Working Group in Peru (2007). Nested PCR for specific diagnosis of Taenia solium taeniasis. J Clin Microbiol, 46(1), 286-9. (Read full article)

Review

  1. Whitcomb B, Lutman C, Pearl M, Medlin E, Prendergast E, Robison K, Burke W (2020). Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement. [Review]. Gynecol Oncol, 157(2), 307-311. (Read full article)
  2. Prendergast EN, Elvin JA (2016). Genomic profiling of gynecologic cancers and implications for clinical practice. [Review]. Curr Opin Obstet Gynecol, 29(1), 18-25. (Read full article)